Elai Katz
Subscribe to Elai Katz's PostsElai Katz is a strategic antitrust lawyer with over two decades of experience handling mergers and acquisitions, litigation, counseling and government investigations. He represents buyers and sellers across a range of industries, including financial services, insurance, healthcare, life sciences, online retail, beverage, airline, and media and telecommunications. Read Elai Katz's full bio.
Heard at the 2025 Antitrust Law Section Spring Meeting
By Lisa P. Rumin, Reese Poncia, Anthony S. Ferrara, Elai Katz, Megan Ingram, Royce Brosseau, Claire Danberg, Betty Zhang and Alex Grayson on Apr 10, 2025
Posted In Cartel Enforcement, Consumer Protection/Privacy, DOJ Developments, EC Developments, FTC Developments, Healthcare Antitrust, Mergers & Acquisitions
The American Bar Association Antitrust Law Section held its annual Spring Meeting from April 2 to 5 in Washington, DC, where federal, state, and international antitrust enforcers shared key updates and enforcement priorities. At the Spring Meeting, antitrust agencies signaled continued scrutiny of mergers, noncompete agreements, and Big Tech – plus an uptick in state-level...
Continue Reading
States Want in on the Merger Review Fun
By Jon B. Dubrow, Elai Katz and Betty Zhang on Aug 8, 2024
Posted In DOJ Developments, FTC Developments, Healthcare Antitrust, Joint Ventures/Competitor Collaboration, Mergers & Acquisitions
WHAT HAPPENED While they have long taken a back seat to federal merger reviews, US states are becoming increasingly involved in merger reviews, including potentially requiring premerger notifications on a broad scale. On July 24, 2024, the Uniform Law Commission adopted its Uniform Antitrust Pre-Merger Notification Act (Model Act) as model legislation for states to...
Continue Reading
How Orange Book Antitrust Scrutiny Is Intensifying
By Elai Katz, Lisa P. Rumin and Betty Zhang on Aug 1, 2024
Posted In FTC Developments, Healthcare Antitrust, IP Antitrust, Monopolization/Abuse of Dominance
Pharmaceutical patent holders beware: Over the past year, antitrust enforcers have taken a more aggressive approach challenging Orange Book listings as an anticompetitive practice. According to the Federal Trade Commission, improperly listing patents in the Orange Book constitutes an unfair method of competition, among other violations. In this article, Elai Katz, Lisa Rumin and Betty...
Continue Reading
